In Good Company• Nov 12, 2025• 45:25Interview

Ester Baiget - CEO of Novonesis | Podcast | In Good Company | Norges Bank Investment Management

From In Good Company

Ester Baiget•CEO, Novonesis

Executive Summary

Novonesis is a leading biosolutions company using enzymes and microbes to replace fossil-fuel-based products in a $1 trillion specialty chemicals market.
The company has a strong competitive moat, characterized by a 10% R&D investment rate, a vast library of 100,000 microbial strains, and products that are a small (1-5%) but critical component of customers' costs.
A strategic shift to value-based pricing, moving from 1-2% annual price erosion to 1-2% price increases, is driving strong financial performance, including a 37% EBIT margin.
Novonesis leverages AI to dramatically accelerate innovation, reducing the time to predict a protein's structure from one year to under a minute, enhancing its ability to create tailor-made solutions.

8 quotes

Concerns Raised

The biggest threat is a failure to correctly prioritize among the company's numerous growth opportunities.
Slow and lengthy regulatory approval processes, particularly in Europe, can hinder the speed of innovation and market penetration.

Opportunities Identified

Displacing products in the $1 trillion specialty chemicals market with sustainable biosolutions.
Developing enzymes for the infinite recycling of PET plastics with lower energy consumption.
Expanding into high-value specialized proteins for nutritional applications.
The potential for existing biosolutions to reduce global CO2 emissions by 5% and create $800 billion in economic productivity.

Key Themes

The Power of Biosolutions

Novonesis is at the forefront of replacing traditional, fossil-based chemicals with nature-inspired enzymes and microbes. These solutions are applied across diverse industries like food, detergents, and biofuels, enabling benefits such as lower-temperature washing, cleaner food labels, and more efficient energy production.

This theme is critical as it positions the company as a key enabler of global sustainability goals, with the CEO claiming existing biosolutions could cut planetary CO2 emissions by 5% and generate $800 billion in economic productivity.

Dominant Market Position & Competitive Moat

The company's strength is built on a foundation of deep scientific expertise, including a massive library of microbial strains, significant R&D investment (10% of revenue), and global scale. Its products represent a small fraction of a customer's cost of goods (1-5%) but deliver immense value, creating high customer stickiness and pricing power.

This durable competitive advantage allows Novonesis to outgrow its end markets by 2-4x and sustain exceptionally high profitability (37% EBIT margin), making it a formidable player in its field.

AI-Accelerated Innovation

Novonesis has integrated AI and advanced analytics deep into its R&D process, transforming its innovation capabilities. The company has reduced the time to predict a protein's shape after a single amino acid change from a year of lab work to mere seconds, drastically speeding up the development of new, high-performance solutions.

This technological edge allows the company to respond to customer needs faster, develop more effective tailor-made solutions, and maintain its leadership position in a rapidly evolving scientific landscape.

Strategic Shift to Value-Based Pricing

The company has successfully implemented a new pricing discipline, shifting from a historical 1-2% annual price erosion to a 1-2% annual price increase. This is achieved by systematically having conversations with customers about the shared value its products create, rather than only pricing at product launch.

This strategic change is a significant driver of revenue growth and margin expansion, demonstrating the company's strong pricing power and its confidence in the indispensable value it provides to customers.

Navigating Global Regulatory Landscapes

The company's growth and product deployment are significantly influenced by varying regulatory timelines across the globe. For example, registering a microbe to replace a fertilizer can take six to eight years in Europe versus only two years in Brazil, creating different go-to-market speeds and strategic priorities.

Understanding and navigating these regulatory differences is a key operational challenge and a strategic factor that can dictate which markets the company prioritizes for new product introductions.

Get started free

Topics

Processed Apr 5, 2026 yt-dlp + mlx-whisper + Gemini